U.S. markets closed
  • S&P Futures

    4,407.00
    -8.00 (-0.18%)
     
  • Dow Futures

    34,945.00
    -53.00 (-0.15%)
     
  • Nasdaq Futures

    15,026.25
    -20.00 (-0.13%)
     
  • Russell 2000 Futures

    2,212.00
    -7.40 (-0.33%)
     
  • Crude Oil

    70.10
    -0.46 (-0.65%)
     
  • Gold

    1,813.80
    -0.30 (-0.02%)
     
  • Silver

    25.61
    +0.03 (+0.11%)
     
  • EUR/USD

    1.1872
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.1760
    +0.0020 (+0.17%)
     
  • Vix

    18.04
    -1.42 (-7.30%)
     
  • GBP/USD

    1.3921
    +0.0006 (+0.04%)
     
  • USD/JPY

    108.9660
    -0.0840 (-0.08%)
     
  • BTC-USD

    38,418.30
    -497.35 (-1.28%)
     
  • CMC Crypto 200

    938.57
    -4.88 (-0.52%)
     
  • FTSE 100

    7,105.72
    +24.00 (+0.34%)
     
  • Nikkei 225

    27,584.41
    -57.42 (-0.21%)
     

G1 Therapeutics to Present at Investor Conferences in March 2020

RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that the company will present corporate updates at the following investor conferences in March 2020:

  • Cowen & Company 40th Annual Healthcare Conference: Chief Financial Officer Jennifer Moses will present on March 2, 2020 at 4:10 p.m. ET

  • Raymond James 41st Annual Institutional Investors Conference: Chief Executive Officer Mark Velleca, M.D., Ph.D., will present on March 2, 2020 at 1:40 p.m. ET

  • Barclays Global Healthcare Conference: Chief Executive Officer Mark Velleca, M.D., Ph.D., will present on March 10, 2020 at 8:30 a.m. ET

To access live and archived webcasts of these presentations, please visit the Events & Presentations page of the G1 website.

About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. Trilaciclib is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy. Trilaciclib has received Breakthrough Therapy Designation from the FDA; a rolling NDA submission for small cell lung cancer is expected to be completed in the second quarter of 2020. Rintodestrant (formerly G1T48) is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. Lerociclib is a differentiated oral CDK4/6 inhibitor designed to enable more effective combination treatment strategies.

G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contact:
Jeff Macdonald
Senior Director, Investor Relations & Corporate Communications
919-907-1944
jmacdonald@g1therapeutics.com